Montgomery-Åsberg Depression Rating Scale (MADRS)

Why use it

The MADRS provides a validated, internationally standardized, clinician-rated assessment of depressive severity that is: (1) more sensitive to antidepressant-related change than the HAM-D; (2) free of somatic items that confound depression rating in medically ill patients (e.g., weight, psychomotor items); (3) widely used across clinical trials enabling cross-study comparison; (4) validated in inpatient, outpatient, and primary care settings; (5) available in over 30 validated language translations. It is the most commonly used primary endpoint in antidepressant clinical trials and is now increasingly used in clinical practice to document treatment response and remission.

About

The Montgomery-Åsberg Depression Rating Scale (MADRS) is a validated, clinician-administered 10-item rating scale designed to measure the severity of depressive episodes and to be sensitive to antidepressant treatment-related change. Developed by Stuart Montgomery and Marie Åsberg and published in the British Journal of Psychiatry in 1979, the MADRS was explicitly constructed to be more sensitive to therapeutic change than older scales such as the Hamilton Depression Rating Scale (HDRS/HAM-D). Each of the 10 items is rated on a 7-point Likert scale from 0 to 6 (with anchor points at 0, 2, 4, and 6 and intermediate scores of 1, 3, 5 for gradations between anchors), generating a total score of 0 to 60. The items assess: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The MADRS is the primary or co-primary endpoint in the majority of randomized controlled trials of antidepressant pharmacotherapy and TMS/ECT trials worldwide. Unlike the PHQ-9 (self-report, DSM-based) and MDI (self-report, ICD/DSM diagnostic), the MADRS is clinician-rated and optimized for sensitivity to symptom change over time — making it the gold standard for antidepressant drug development and clinical research.

When to use

• Baseline severity rating before initiating pharmacological or psychological treatment for major depressive disorder
• Serial assessment to measure treatment response — administer at baseline, then every 2–4 weeks during acute treatment phase
• Defining remission in clinical research: MADRS ≤10 is the most widely used remission criterion
• Measurement-based care in psychiatry clinics — provides objective tracking of symptom burden over treatment course
• Assessment of antidepressant augmentation decisions: if MADRS has not reduced by ≥50% from baseline at 4–6 weeks, consider augmentation or switch
• Rating depressive symptoms in medically ill patients where somatic overlap items (appetite, sleep, energy) on HAM-D may reflect physical illness rather than depression
• Clinical trials of antidepressants, neuromodulation (TMS, ECT), and psychotherapy as a primary endpoint measure

Formula

Pearls & pitfalls

• Item 10 (Suicidal Thoughts) should ALWAYS be evaluated first or highlighted — any score ≥4 on this item (i.e., suicidal ideation with plan or intent) requires immediate safety assessment regardless of total MADRS score.
• The standard MADRS remission threshold is ≤10. Response is defined as ≥50% reduction from baseline score. These are the endpoints used in most regulatory filings and clinical trials.
• The MADRS is rated by a clinician based on a semi-structured interview covering the past 7 days. The ratings reflect the AVERAGE severity over this period, not the worst moment.
• Unlike the HAM-D (which includes items on somatic anxiety, gastrointestinal symptoms, and psychomotor agitation), the MADRS is free of somatic overlap items, making it more appropriate for depression assessment in patients with physical illness where somatic symptoms may reflect medical rather than psychiatric pathology.
• The MADRS uses 0–6 scoring with anchor descriptions at 0, 2, 4, and 6 — scores of 1, 3, and 5 represent intermediate severity. Clinicians should feel free to use odd numbers when the symptom falls between anchors.
• Inter-rater reliability of the MADRS is good to excellent (ICC 0.89–0.97) when administrated by trained clinicians using a structured interview (e.g., SIGMA — Structured Interview Guide for MADRS).
• The MADRS is significantly more sensitive to antidepressant-induced change than the HAM-D 17-item scale — this is its primary design advantage and explains its dominance in antidepressant trials.
• The Computerized Adaptive Diagnostic-MADRS (CAD-MADRS) and MADRS-S (self-rated version) are available for clinical practice settings where clinician administration is not feasible.
• MADRS scores in clinical trials: A change of ≥1.6 points represents the minimal clinically important difference (MCID). A 6–8 point reduction from baseline is clinically meaningful.

Next steps

MADRS 0–6 (No/Minimal Depression): No depressive episode. Reassure. Reassess if symptoms emerge or worsen. MADRS 7–19 (Mild Depression): Mild depressive episode. Consider structured psychotherapy (CBT, behavioral activation) as first-line. Antidepressant pharmacotherapy may be initiated. Reassess at 2–4 weeks. MADRS 20–34 (Moderate Depression): Moderate depressive episode. Combined pharmacotherapy + psychotherapy recommended. Structured specialist follow-up. Reassess MADRS at 4 and 8 weeks. If MADRS has not reduced ≥50% at 4–6 weeks, consider augmentation or switching antidepressant. MADRS 35–60 (Severe Depression): Severe depressive episode. Urgent psychiatric evaluation. Antidepressant ± mood stabilizer or atypical antipsychotic augmentation. Consider inpatient admission if safety risk. ECT should be considered for severe treatment-resistant, psychotic, or catatonic depression. Always assess suicidal ideation (Item 10) regardless of total score.

Evidence

Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389. PMID:444788. Original validation in 65 patients with primary depressive illness. Correlation with HAM-D r=0.80. High inter-rater reliability (ICC 0.97). Internal consistency Cronbach α=0.84–0.94. Validated in numerous languages and clinical populations. Lobo A et al. Validation of the Spanish versions of the Montgomery-Asberg Depression and Hamilton Anxiety Rating Scales. Med Clin. 2002;118(13):493-499. MADRS remission threshold ≤10: established in multiple regulatory filings (FDA, EMA) for antidepressant approval.

References

1. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389. — link
2. Svanborg P, Åsberg M. A comparison between the Beck Depression Inventory (BDI) and the self-rating version of the Montgomery Åsberg Depression Rating Scale (MADRS). J Affect Disord. 2001;64(2-3):203-216. — link
3. Williams JB. Standardizing the Hamilton Depression Rating Scale: past, present, and future. Eur Arch Psychiatry Clin Neurosci. 2001;251(Suppl 2):II6-12. — link
4. Hawley CJ et al. The use of the Montgomery Åsberg Depression Rating Scale (MADRS) in everyday clinical practice. Ann Gen Psychiatry. 2002;1(1):1. — link
5. Zimmerman M et al. How should remission from depression be defined? The depressed patient's perspective. Am J Psychiatry. 2006;163(1):148-150. — link